Compare LQDA & RYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | RYN |
|---|---|---|
| Founded | 2004 | 1926 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 2018 | N/A |
| Metric | LQDA | RYN |
|---|---|---|
| Price | $34.21 | $21.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 4 |
| Target Price | ★ $37.40 | $27.25 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 11-03-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 13.33% |
| EPS Growth | N/A | ★ 373.89 |
| EPS | N/A | ★ 5.07 |
| Revenue | $69,216,000.00 | ★ $1,293,371,000.00 |
| Revenue This Year | $994.17 | N/A |
| Revenue Next Year | $169.25 | N/A |
| P/E Ratio | ★ N/A | $4.28 |
| Revenue Growth | ★ 343.41 | 60.70 |
| 52 Week Low | $11.26 | $21.06 |
| 52 Week High | $36.41 | $28.31 |
| Indicator | LQDA | RYN |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 48.00 |
| Support Level | $33.45 | $21.28 |
| Resistance Level | $36.60 | $21.89 |
| Average True Range (ATR) | 1.41 | 0.54 |
| MACD | -0.25 | 0.04 |
| Stochastic Oscillator | 47.88 | 36.33 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.